In downstream veterinary biologics manufacture, the live Salmonella abortus-equi Vaccine, Live (Strain C39) Veterinary Grade API is handled as a frozen bulk suspension or a lyophilised intermediate, and the first practical constraint occurs before formulation: the organism is not a chemical entity with fixed stability but a Gram-negative population whose batch-to-batch titre fluctuates with fermentation harvest time and chilling rate. For injectable presentations, the harvested suspension is mixed with cryoprotectant and buffering salts in closed stainless-steel vessels. Process holding at 2–8 °C is preferred because metabolic activity and membrane lipid oxidation increase above 8 °C; however, holding below 2 °C can create ice-crystal damage when freezing starts unevenly at the vessel wall. Mixing must be gentle because high-shear impellers above 300 rpm may reduce viable count through hydrodynamic stress. The blend is not terminally sterilised; therefore aseptic assembly follows USDA 9 CFR 113 and Ph. Eur. 0062 for veterinary vaccines, with hygienic transfer lines subjected to clean steam cycles after each batch. Contamination risk from wild-type Salmonella in equine facilities is substantial, so air handling is validated to ISO 14644-1:2015 and surfaces are maintained under 21 CFR 211.113 sanitisation programmes. The final injectable suspension after reconstitution is typically used immediately or within a short window because the stabiliser matrix is diluted and the organism becomes metabolically active; published data for Strain C39-specific post-reconstitution hold times are limited, but general live bacterial vaccine data show viability losses of several logs when held at room temperature beyond 4 h.

What limits viable cell recovery after lyophilization in equine parenteral formulations?

Freeze-drying is the highest-risk unit operation for the live Strain C39 API because the organism must survive both freezing and primary drying without losing the ability to replicate after rehydration. The bulk suspension is filled into vials and loaded onto freeze-dryer shelves; edge-vial heat transfer differences on commercial shelves cause product temperature deviations of 2–5 °C from centre-vial readings. Sucrose and skim-milk matrices are used to create an amorphous glass around the cells, but the collapse temperature of the cake depends on residual salts and buffer ions. A primary drying shelf temperature above the collapse point—commonly in the region of −31 °C to −35 °C for sucrose-rich formulations—produces a collapsed cake with poor reconstitution and accelerated viability loss. Chamber pressure is typically held between 50 µbar and 200 µbar to balance heat transfer and water vapour removal; low pressure reduces gas conduction and can overheat the product surface, while high pressure increases chamber gas density and may slow sublimation. Freezing rate controls the size of intracellular ice crystals: a slower ramp of 0.5–1.0 °C/min is generally preferred for Gram-negative bacterial suspensions to avoid membrane puncture, although the optimal ramp is strain-specific. Residual moisture is measured by Karl Fischer titration according to Ph. Eur. 2.5.12 and is typically maintained below 3%; drier cakes can have higher glass-transition temperatures but may also impose desiccation stress on cell envelopes. Scale-up from laboratory to production shelves is not linear because shelf loading density changes the vapour path length and the radiative heat input from the dryer walls. Published data for the C39 strain across different lyophilisation matrices is limited; manufacturers therefore run matrix-screening arrays rather than assuming transferability from other Salmonella veterinary vaccines.

Oral drench solutions require acid-neutralising stabilisation before administration

Because the equine stomach can fall below pH 2, oral liquid presentations of the live Strain C39 API are formulated with acid-neutralising buffers rather than simple aqueous suspensions. The API is suspended or dissolved from a lyophilised powder in chilled phosphate or bicarbonate buffer immediately before use, with the target vehicle pH held between 6.5 and 7.5. Wet holding at ambient temperature causes cell division and death, so the batch record must specify buffer at 2–8 °C and a maximum use-by window after reconstitution. Mixing of oral drench solutions in high-shear rotor-stator mixers above 2500 rpm is avoided because cavitation and local heating can lyse bacterial membranes. The solution path from mixing vessel to oral dosing gun must be cleaned with alkaline detergents and rinsed with potable water, not disinfectants that leave residues; quaternary ammonium compounds, hydrogen peroxide, and alcohol-based sanitisers are incompatible with live Salmonella antigen. Stability data for Strain C39 in orally administered solutions are sparse, so the formulator must verify viable count after simulated gastric fluid exposure using the challenge conditions of the target species rather than extrapolating from human pharmacopoeial buffers. Preservatives such as benzalkonium chloride, phenol, and chlorhexidine are not added because they reduce viable count even at low concentrations; instead the product is manufactured as a single-dose or short-duration multi-dose pack under aseptic conditions.

Feed premix manufacturing places the live Strain C39 API into direct contact with mineral carriers, vitamins, and trace minerals that can manipulate moisture and redox conditions. The critical processing variable is not the total moisture of the premix but the water activity at the carrier surface; above 0.3 water activity the organism can become metabolically active, while below 0.1 water activity the dried bacterial matrix may lose viability through desiccation. Extruded or pelleted feeds generated at conditioning temperatures above 65 °C are incompatible with live bacterial vaccines unless the API is applied after pelleting by post-acquirement spraying or mixed into a top-dress premix. Ribbon mixers with paddle speeds above 60 rpm generate heat and friction, but the larger risk is segregation: the live powder has a small particle size and low density, so it can migrate to the top of the blend and create superpotent or subpotent pockets. Batch uniformity is monitored by assaying CFU per gram in multiple thief samples under 21 CFR 211.160 laboratory control expectations. For powders and premixes requiring dry granulation, roller compaction is preferred over moist granulation because binder fluid can impose osmotic shock; if moist granulation is unavoidable, non-aqueous binder systems or cold water at 2–8 °C are used with immediate vacuum drying at shelf temperatures below 35 °C. Published data for Strain C39 in equine feed matrices is limited, so premix development requires pre-screening of the exact batch of carrier for pH, water activity, and redox potential before blending.

When tablet compression replaces syringe-based delivery of a live bacterial antigen

Direct compression of lyophilised bacterial powder is an uncommon but technically definable route, ordinarily reserved for oral immunisation programmes where parenteral administration is not feasible. The primary viability stressors are compression pressure and die-wall friction. Direct compression of lyophilised bacterial powder with microcrystalline cellulose and a lubricant must balance tablet hardness against cell survival; hard tablets formed at higher compression force tend to show lower CFU recovery, but the relationship is not linear because cell death occurs mainly at the punch face boundary layer where shear is greatest. For this reason, capsule filling of a lyophilised or spray-dried powder is less destructive than tableting: the powder is dosed into hard gelatin or HPMC capsules without a compaction step. The capsule shell itself is not a protective barrier against gastric acid unless an enteric coating is applied, and enteric coating of capsules containing live organisms is complicated by solvent exposure and coating pan temperature. If tablets are coated, aqueous film coating must be conducted with inlet air temperatures not exceeding 35–40 °C and exhaust humidity controlled below 40% RH; solvent-based coatings are generally unsuitable because residual solvent and drying stress reduce viability. Lubricant selection is also constrained: magnesium stearate above 0.5–1.0% can reduce water penetration into the tablet and alter local pH at the particle surface, but its hydrophobic effect on dissolution may not directly translate to viability loss. Published formulation data for Strain C39 in tablet or capsule form is limited, and the absence of a compendial monograph for this dosage form means that each batch must be justified against a validated in-process CFU assay rather than a fixed hardness specification.

Powder and granule handling under low-humidity isolators

Under low-humidity isolator conditions, dry powder operations for the live Strain C39 API are performed with strict control of moisture uptake because water activity drives metabolic activity and increases the local concentration of reactive ions. The powder is milled or sieved only when necessary; sieve stack vibration at amplitudes above 1.5 mm can fracture agglomerates and reduce viability by mechanical energy, although the exact threshold depends on excipient loading. Low-humidity conditions at 30–40% RH are maintained to prevent electrostatic adhesion and to preserve cake structure; at relative humidity above 60% many stabiliser systems undergo deliquescence and the powder becomes sticky, making uniform blending impossible. The handling area must use compressed air meeting ISO 8573-1:2010 class 2.2.1 or better to exclude oil and water vapour. Powders and granules for reconstitution are filled into amber glass vials or double-polyethylene bags, then sealed with residual moisture monitoring by Karl Fischer titration per Ph. Eur. 2.5.12. Cold-chain shipping validation is typically conducted under ASTM D4169-22 profiles to determine whether physical shock or temperature excursions during transport alter the CFU titre; frozen shipping does not remove the requirement for temperature loggers because freeze-thaw cycles damage the cytoplasmic membrane. Live bacterial powders and granules are not irradiated, not ethylene-oxide treated, and not steam-sterilised, because any of these terminal processes destroys the active ingredient.